EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer

Shipra Shukla, Dan Li, Woo Hyun Cho, Dana M Schoeps, Holly M Nguyen, Jennifer L Conner, Marjorie L Roskes, Anisha Tehim, Gabriella Bayshtok, Mohini R Pachai, Juan Yan, Nicholas A Teri und 9 weitere

Journal of Clinical Investigation · 2025

DOI: 10.1172/jci180378 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2025. Verfasst von Shipra Shukla und 20 weiteren Autor:innen. Beteiligte Einrichtung: Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Transcription Factors, Transcriptome, Gene Expression Regulation, Neoplastic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantTranscription FactorsTranscriptomeGene Expression Regulation, NeoplasticNeoplasm ProteinsMaleHumansAnimalsMiceCell Line, TumorXenograft Model Antitumor AssaysHepatocyte Nuclear Factor 4Cell Cycle ProteinsReceptors, AndrogenBromodomain Containing Proteins

Stichwörter der Autor:innen

Cell biologyDrug therapyEpigeneticsGeneticsOncology

Substanzen

Transcription FactorsHepatocyte Nuclear Factor 4Neoplasm ProteinsCell Cycle ProteinsBRD4 protein, humanReceptors, AndrogenBromodomain Containing Proteins

Autor:innen und Institutionen

  • Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of Urology, University of Washington, Seattle, Washington, USA.
  • Weill Cornell Medicine, New York, New York, USA.
  • Weill Cornell Medical College, New York, New York, USA.
  • Zenith Epigenetics, Calgary, Alberta, Canada.
  • Triana Biomedicines, Waltham, Massachusetts.

Förderung

  • NCI NIH HHS
  • National Cancer Institute

Zitieren

APA

Shukla, S., Li, D., Cho, W. H., Schoeps, D. M., Nguyen, H. M., Conner, J. L., Roskes, M. L., Tehim, A., Bayshtok, G., Pachai, M. R., Yan, J., Teri, N. A., Campeau, E., Attwell, S., Trojer, P., Ostrovnaya, I., Gopalan, A., Khurana, E., Corey, E., …, & Chen, Y. (2025). BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer. Journal of Clinical Investigation. https://doi.org/10.1172/jci180378

Vancouver

Shukla S, Li D, Cho WH, Schoeps DM, Nguyen HM, Conner JL, et al. BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer. Journal of Clinical Investigation. 2025. doi:10.1172/jci180378

BibTeX
@article{Shukla2025,
  author = {Shukla, Shipra and Li, Dan and Cho, Woo Hyun and Schoeps, Dana M and Nguyen, Holly M and Conner, Jennifer L and Roskes, Marjorie L and Tehim, Anisha and Bayshtok, Gabriella and Pachai, Mohini R and Yan, Juan and Teri, Nicholas A and Campeau, Eric and Attwell, Sarah and Trojer, Patrick and Ostrovnaya, Irina and Gopalan, Anuradha and Khurana, Ekta and Corey, Eva and Chi, Ping and Chen, Yu},
  title = {BET inhibitors reduce tumor growth in preclinical models of gastrointestinal gene signature–positive castration-resistant prostate cancer},
  journal = {Journal of Clinical Investigation},
  year = {2025},
  doi = {10.1172/jci180378}
}
Kostenlos starten →